Press Releases Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Real-time Estimate Cboe BZX Other stock markets 08:50:55 13/05/2024 pm IST			5-day change	1st Jan Change
7.51 ^USD	+0.81%		-3.88%	-39.30%

09/05	Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	CI
07/05	Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	09/05	BU
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results	08/05	BU
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000	02/05	BU
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024	25/04	BU
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results	29/03	BU
Pulse Biosciences Announces Plans to Initiate a Rights Offering	29/03	BU
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024	15/03	BU
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System	08/03	BU
PULSE BIOSCIENCES ANNOUNCES POSITIVE 60-DAY FOLLOW-UP EVALUATIONS FOR INITIAL PATIENTS TREATED IN THE CELLFX NSPFA 360-degree CARDIAC CATHETER FIRST-IN-HUMAN FEASIBILITY STUDY	15/02	AQ
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study	14/02	BU
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium	31/01	BU
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp	02/01	BU
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter	20/12	BU
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode	21/11	BU
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference	16/11	BU
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results	13/11	BU
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call	11/11	BU
Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023	31/23/31	BU
Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery	24/23/24	BU
PULSE BIOSCIENCES NANOSECOND PULSED FIELD ABLATION CIRCUMFERENTIAL CATHETER SYSTEM TO BE FEATURED IN A PRESENTATION AT THE GLOBAL EP SUMMIT	02/23/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Press Releases

Filters